Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design
Funding
Conflicts of Interest
List of Contributions
- Nayan, M.U.; Panja, S.; Sultana, A.; Zaman, L.A.; Vora, L.K.; Sillman, B.; Gendelman, H.E.; Edagwa, B. Polymer Delivery Systems for Long-Acting Antiretroviral Drugs. Pharmaceutics 2024, 16, 183. https://doi.org/10.3390/pharmaceutics16020183.
- Curley, P.; Hobson, J.J.; Liptrott, N.J.; Makarov, E.; Al-Khouja, A.; Tatham, L.; David, C.A.W.; Box, H.; Neary, M.; Sharp, J.; et al. Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations. Pharmaceutics 2023, 15, 1835. https://doi.org/10.3390/pharmaceutics15071835.
- Kinsale, T.S.; Cottrell, M.L.; Li, L.; Brand, R.; Gatto, G.; Luecke, E.; Norton, C.; Krovi, A.; Dumond, J.B.; Rao, G.; et al. Pharmacokinetic Modeling to Guide Preclinical Development of an Islatravir-Eluting Reservoir-Style Biodegradable Implant for Long-Acting HIV PrEP. Pharmaceutics 2024, 16, 201. https://doi.org/10.3390/pharmaceutics16020201.
- Daly, M.B.; Wong-Sam, A.; Li, L.; Krovi, A.; Gatto, G.J.; Norton, C.; Luecke, E.H.; Mrotz, V.; Forero, C.; Cottrell, M.L.; et al. Pharmacokinetic Study of Islatravir and Etonogestrel Implants in Macaques. Pharmaceutics 2023, 15, 2676. https://doi.org/10.3390/pharmaceutics15122676.
- Young, I.C.; Thorson, A.L.; Shrivastava, R.; Sykes, C.; Schauer, A.P.; Cottrell, M.L.; Kashuba, A.D.M.; Benhabbour, S.R. Dose-Ranging Plasma and Genital Tissue Pharmacokinetics and Biodegradation of Ultra-Long-Acting Cabotegravir In Situ Forming Implant. Pharmaceutics 2023, 15, 1487. https://doi.org/10.3390/pharmaceutics15051487.
- Mayer, B.T.Z.L.; de Camp, A.C.; Yu, C.; Sato, A.; Angier, H.; Seaton, K.E.; Yates, N.; Ledgerwood, J.E.; Mayer, K.; Caskey, M.; et al. Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV. Pharmaceutics 2024, 16, 594. https://doi.org/10.3390/pharmaceutics16050594.
- Kinvig, H.; Rajoli, R.K.R.; Pertinez, H.; Vora, L.K.; Volpe-Zanutto, F.; Donnelly, R.F.; Rannard, S.; Flexner, C.; Siccardi, M.; Owen, A. Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans. Pharmaceutics 2023, 15, 2709. https://doi.org/10.3390/pharmaceutics15122709.
- Vora, L.K.; Tekko, I.A.; Zanutto, F.V.; Sabri, A.; Choy, R.K.M.; Mistilis, J.; Kwarteng, P.; Jarrahian, C.; McCarthy, H.O.; Donnelly, R.F. A Bilayer Microarray Patch (MAP) for HIV Pre-Exposure Prophylaxis: The Role of MAP Designs and Formulation Composition in Enhancing Long-Acting Drug Delivery. Pharmaceutics 2024, 16, 142. https://doi.org/10.3390/pharmaceutics16010142.
- Peet, M.M.; Agrahari, V.; Clark, M.R.; Doncel, G.F. Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention. Pharmaceutics 2024, 16, 348. https://doi.org/10.3390/pharmaceutics16030348.
References
- Wulandari, L.P.L.; He, S.Y.; Fairley, C.K.; Bavinton, B.R.; Marie-Schmidt, H.; Wiseman, V.; Guy, R.; Tang, W.; Zhang, L.; Ong, J.J. Preferences for pre-exposure prophylaxis for HIV: A systematic review of discrete choice experiments. EClinicalMedicine 2022, 51, 101507. [Google Scholar] [CrossRef] [PubMed]
- AVAC. 2025. Available online: https://data.prepwatch.org/ (accessed on 18 April 2025).
- Zhang, J.; Li, C.; Xu, J.; Hu, Z.; Rutstein, S.E.; Tucker, J.D.; Ong, J.J.; Jiang, Y.; Geng, W.; Wright, S.T.; et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: A global systematic review and meta-analysis. Lancet HIV 2022, 9, e254–e268. [Google Scholar] [CrossRef] [PubMed]
- Rogers, B.G.; Chan, P.A.; Sutten-Coats, C.; Zanowick-Marr, A.; Patel, R.R.; Mena, L.; Goedel, W.C.; Chu, C.; Silva, E.; Galipeau, D.; et al. Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the United States. BMC Public Health 2023, 23, 1643. [Google Scholar] [CrossRef] [PubMed]
- Nair, G.; Celum, C.; Szydlo, D.; Brown, E.R.; Akello, C.A.; Nakalega, R.; Macdonald, P.; Milan, G.; Palanee-Phillips, T.; Reddy, K.; et al. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: A randomised, open-label, crossover trial. Lancet HIV 2023, 10, e779–e789. [Google Scholar] [CrossRef] [PubMed]
- Griffin, J.B.; Ridgeway, K.; Montgomery, E.; Torjesen, K.; Clark, R.; Peterson, J.; Baggaley, R.; van der Straten, A. Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis. PLoS ONE 2019, 14, e0224898. [Google Scholar] [CrossRef] [PubMed]
- Molina, J.M.; Ghosn, J.; Assoumou, L.; Delaugerre, C.; Algarte-Genin, M.; Pialoux, G.; Katlama, C.; Slama, L.; Liegeon, G.; Beniguel, L.; et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): A prospective observational cohort study. Lancet HIV 2022, 9, e554–e562. [Google Scholar] [CrossRef] [PubMed]
- Molina, J.M.; Capitant, C.; Spire, B.; Pialoux, G.; Cotte, L.; Charreau, I.; Tremblay, C.; Le Gall, J.M.; Cua, E.; Pasquet, A.; et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N. Engl. J. Med. 2015, 373, 2237–2246. [Google Scholar] [CrossRef] [PubMed]
- Young, I.C.; Massud, I.; Cottrell, M.L.; Shrivastava, R.; Maturavongsadit, P.; Prasher, A.; Wong-Sam, A.; Dinh, C.; Edwards, T.; Mrotz, V.; et al. Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection. Nat. Commun. 2023, 14, 708. [Google Scholar] [CrossRef] [PubMed]
- Young, I.C.; Pallerla, A.; Cottrell, M.L.; Maturavongsadit, P.; Prasher, A.; Shrivastava, R.; De la Cruz, G.; Montgomery, S.A.; Schauer, A.; Sykes, C.; et al. Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy. J. Control. Release 2023, 363, 606–620. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
García-Lerma, J.G. Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design. Pharmaceutics 2025, 17, 742. https://doi.org/10.3390/pharmaceutics17060742
García-Lerma JG. Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design. Pharmaceutics. 2025; 17(6):742. https://doi.org/10.3390/pharmaceutics17060742
Chicago/Turabian StyleGarcía-Lerma, J. Gerardo. 2025. "Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design" Pharmaceutics 17, no. 6: 742. https://doi.org/10.3390/pharmaceutics17060742
APA StyleGarcía-Lerma, J. G. (2025). Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design. Pharmaceutics, 17(6), 742. https://doi.org/10.3390/pharmaceutics17060742